5F-MDMB-2201 is an indazole-based synthetic cannabinoid that acts as a potent agonist of the CB₁ receptor. Thus ,it is sold online as a designer drug. Pfizer invented this drug in 2008. However,it is a potent cannabinoid agonists.
5F-MDMB-2201 is an indazole-based synthetic cannabinoid (CB) that is structurally related to AB-FUBINACA. A 4-fluorophenyl group substitutes the cyclohexyl group. Consequently,it has a high affinity ligand for the central CB1. It bears a cyclohexyl group,thus it is structurally related to AB-CHMINACA. However, the methyl ester group replaces the terminal aminocarbonyl moiety and the tert-butyl group substitutes the isobutyl moiety. This compound has unknown physiological and toxicological properties. Also, forensic and research applications are the uses of this product.
Additional information
Quantities
10g, 50g, 100g, 500g, 1000g
Reviews
There are no reviews yet.
Be the first to review “5F-MDMB 2201” Cancel reply
Reviews
There are no reviews yet.